


Amendments to the Claims:

The following is a complete list of claims indicating the changes incorporated by the present amendment and replacing all prior versions of the claims. Any claims canceled herein and all deletions made in claims that are not canceled herein are done so without prejudice to being re-instituted at a later date in this or a related application.

Listing of Claims:

1. **(Currently Amended)** A compound having the formula:



wherein

R⁹ and R¹⁰ are members independently selected from H, substituted or unsubstituted alkyl and acyl;

R³ is H;

R⁴ is selected from H, -OMe and -OH;

R⁵ is OR¹⁴, wherein R¹⁴ is a member selected from H and unsubstituted alkyl;


R⁶ is OR¹⁴, wherein R¹⁴ is a member selected from H, substituted or unsubstituted alkyl and P(O)(OR¹⁷)(OR¹⁷), wherein each R¹⁷ is independently selected from substituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted phenyl,

wherein a member selected from R⁵ and R³; and R⁶ and R³ together with the atoms to which they are attached are optionally joined to form a ring system selected from substituted or unsubstituted heterocycloalkyl; and

R⁸ is selected from the group consisting of H and unsubstituted alkyl.

2.-7. (Canceled)

8. (Original) The compound according to claim 1, wherein R⁶ has the formula:



in which


R²² is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

L is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

Ar is a member selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.

9. (Original) The compound according to claim 8, wherein L comprises a moiety that is cleaved *in vivo* after entry of said compound into a cell.

10. (Original) The compound according to claim 1, wherein R⁶ has the formula:



in which

R²² is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

L is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

n is an integer from 1 to 30.

11. (Original) The compound according to claim 10, wherein L comprises a moiety that is cleaved *in vivo* after entry of said compound into a cell.

12. (Original) A formulation of the compound according to claim 1, and a second compound having the formula:

A-B

wherein

A is a hydrophobic domain; and

B is a hydrophilic domain covalently bound to A.

13. (Original) The formulation according to claim 12, further comprising a polycationic species.

14. (Original) The formulation according to claim 13, wherein said polycationic species is a dendrimeric polyamine.

15. (Original) The formulation according to claim 12, wherein said formulation is an aqueous formulation.

16.-28. (Canceled)